ع
Johnson & Johnson will disburse $5.5 billion under the settlement to resolve claims linked to its talcum powder products, the company said in a statement. The agreement covers a significant portion of pending cases in U.S. courts where plaintiffs alleged the products caused cancer. Court records reviewed by Reuters show the firm has confronted more than 50,000 such claims since litigation intensified in the last decade.
The payment will be made in installments over several years to ease the financial impact on the company’s balance sheet, according to the statement. Johnson & Johnson has maintained that its talc products are safe and asbestos-free, describing the deal as a means to achieve finality on the matter. A separate analysis by Bloomberg noted that the settlement amount aligns with earlier provisions the company had set aside for legal contingencies.
This resolution follows years of trials and appeals that produced mixed verdicts across different states, industry data from the U.S. Chamber Institute for Legal Reform indicates. Some earlier jury awards reached into the billions before being reduced or overturned on appeal. The latest accord is expected to compensate eligible claimants through an established claims process managed by neutral administrators.
Johnson & Johnson reported global sales of $94.9 billion in 2025, according to its annual filing with the U.S. Securities and Exchange Commission, providing context for the scale of the settlement relative to its overall operations. The company said the payout would not affect its ability to invest in pharmaceutical research and medical devices. Analysts at Goldman Sachs projected limited long-term effects on earnings per share following the announcement.
The settlement does not include an admission of liability, the company emphasized in its release. Plaintiffs’ lawyers involved in the negotiations described the figure as a substantial recovery for those affected, though some advocacy groups called for higher compensation in remaining cases. Additional details on distribution will be filed with overseeing courts in the coming weeks, according to parties familiar with the agreement.
Regulatory oversight of cosmetic talc has evolved since the first lawsuits surfaced, with the U.S. Food and Drug Administration issuing updated testing guidelines in 2022 that the agency said aimed to improve detection of trace contaminants. Johnson & Johnson discontinued sales of its talc-based baby powder in the United States and Canada in 2020, shifting entirely to cornstarch formulations, the company previously stated. The move came as part of a broader industry review of ingredient safety standards.
